Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Sep 25:8:661.
doi: 10.3389/fphar.2017.00661. eCollection 2017.

Purinergic Signalling: Therapeutic Developments

Geoffrey Burnstock  1   2
Affiliations
Review

Purinergic Signalling: Therapeutic Developments

Geoffrey Burnstock. Front Pharmacol. .

Abstract

Purinergic signalling, i.e., the role of nucleotides as extracellular signalling molecules, was proposed in 1972. However, this concept was not well accepted until the early 1990's when receptor subtypes for purines and pyrimidines were cloned and characterised, which includes four subtypes of the P1 (adenosine) receptor, seven subtypes of P2X ion channel receptors and 8 subtypes of the P2Y G protein-coupled receptor. Early studies were largely concerned with the physiology, pharmacology and biochemistry of purinergic signalling. More recently, the focus has been on the pathophysiology and therapeutic potential. There was early recognition of the use of P1 receptor agonists for the treatment of supraventricular tachycardia and A2A receptor antagonists are promising for the treatment of Parkinson's disease. Clopidogrel, a P2Y12 antagonist, is widely used for the treatment of thrombosis and stroke, blocking P2Y12 receptor-mediated platelet aggregation. Diquafosol, a long acting P2Y2 receptor agonist, is being used for the treatment of dry eye. P2X3 receptor antagonists have been developed that are orally bioavailable and stable in vivo and are currently in clinical trials for the treatment of chronic cough, bladder incontinence, visceral pain and hypertension. Antagonists to P2X7 receptors are being investigated for the treatment of inflammatory disorders, including neurodegenerative diseases. Other investigations are in progress for the use of purinergic agents for the treatment of osteoporosis, myocardial infarction, irritable bowel syndrome, epilepsy, atherosclerosis, depression, autism, diabetes, and cancer.

Keywords: ATP; CNS diseases; adenosine; infection; inflammation; peripheral diseases.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Abdulqawi R., Dockry R., Holt K., Layton G., Mccarthy B. G., Ford A. P., et al. (2015). P2X3 receptor antagonist (AF-219) in refractory chronic cough: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 385 1198–1205. 10.1016/S0140-6736(14)61255-1 - DOI - PubMed
    1. Able S. L., Fish R. L., Bye H., Booth L., Logan Y. R., Nathaniel C., et al. (2011). Receptor localization, native tissue binding and ex vivo occupancy for centrally penetrant P2X7 antagonists in the rat. Br. J. Pharmacol. 162 405–414. 10.1111/j.1476-5381.2010.01025.x - DOI - PMC - PubMed
    1. Abraham M. K., Nolte A., Reus R., Behring A., Zengerle D., Avci-Adali M., et al. (2015). In vitro study of a novel stent coating using modified CD39 messenger RNA to potentially reduce stent angioplasty-associated complications. PLOS ONE 10:e0138375 10.1371/journal.pone.0138375 - DOI - PMC - PubMed
    1. Acevedo C. G., Huambachano A., Perez E., Rojas S., Bravo I., Contreras E. (1997). Effect of ethanol on human placental transport and metabolism of adenosine. Placenta 18 387–392. 10.1016/S0143-4004(97)80038-0 - DOI - PubMed
    1. Adinolfi E., Capece M., Franceschini A., Falzoni S., Giuliani A. L., Rotondo A., et al. (2015). Accelerated tumor progression in mice lacking the ATP receptor P2X7. Cancer Res. 75 635–644. 10.1158/0008-5472.CAN-14-1259 - DOI - PubMed